Dominick Bosse, MD

Articles by Dominick Bosse, MD

Dr. Bosse Discusses Bone-Targeted Agents in RCC

March 13th 2018

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses bone-targeted agents for patients with renal cell carcinoma (RCC).

Dr. Bosse on the Quality of Life With VEGF Plus Radium-223

ByDominick Bosse, MD

October 17th 2017

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the quality of life when combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma (mRCC).

Dr. Bosse on the Safety Profile With Radium-223 Plus VEGF in RCC

ByDominick Bosse, MD

October 9th 2017

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the safety profile demonstrated with the combination of radium-223 and VEGF-targeted therapy for patients with renal cell carcinoma (RCC).

Dr. Bosse on Rationale Behind Study of VEGF Plus Radium-223 in RCC

ByDominick Bosse, MD

September 21st 2017

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the rationale behind combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma.